Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adrecizumab Phase 1 in Healthy Volunteers
NCT02991508Phase 1Completed
- Sponsor
- Radboud University Medical Center
- Start
- May 2016
- Primary completion
- Sep 2016
- Modality
- IgG Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of adrecizumab in sepsis (4 arms), sponsored by Radboud University Medical Center. Primary endpoint: Total number of treatment related (serious) adverse events at 3 months. Started May 2016; status: completed.
02
Drugs
adrecizumab
03
Conditions
sepsis
Beyond the preview
Go deeper on NCT02991508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02991508.